With better access to tools like CCTA and diagnostic tools that leverage CCTA, clinicians can better support their patients in managing overall cardiovascular health, patients will benefit from less invasive care and enhanced quality of life, and health systems could ultimately see reduced costs and streamlined workflows.
Highly preventable if diagnosed and managed early, CAD should be a healthcare priority. Both patients and providers have pivotal roles in driving this change.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Five ways stakeholders can promote screening and treatment for elevated Lp(a) in the future to improve overall cardiac disease mortality
Findings published in Journal of American College of Cardiology found Cleerly's AI platform matched or outperformed core lab quantitative coronary angiography (QCA), core lab–interpreted coronary computed tomography angiography (CTA), and invasive fractional flow reserve (FFR) for evaluating the severity of coronary arterial stenosis.
With the extension to its Series A financing, XyloCor plans a clinical trial testing its gene therapy as an adjunct to coronary artery bypass graft surgery. A study in refractory angina is already underway.
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
The new Japanese reimbursement policy will go into effect on Dec. 1 and follows positive coverage decisions by Medicare and the United Kingdom’s National Health Services.
Abbott touted its Absorb fully-resorbable coronary scaffold but physicians never saw clear clinical benefit over the standard of treatment leading the company to halt sales of the expensive device just over a year after FDA approval.
Abbott's Absorb is a long-awaited, much-hyped technology to battle coronary artery disease, but its immediate success is not guaranteed.
Ever since the internet became a thing, consumers have used it to discuss health issues, especially over the last 10 years as social media became a daily destination for millions of people. Something that’s also true: women have typically underestimated heart disease. But here’s some good anecdotal evidence that women have found their voice. The […]
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.